| Unknown | Treatment of (IDA) by (FPC) Delivered Via Infusion Pump in Patients Receiving Home Infusion Therapy Iron Deficiency Anemia | Phase 2 | 2021-11-30 |
| Completed | Triferic AVNU Infusion Via Freedom Pump During Hemodialysis End Stage Renal Disease | Phase 4 | 2021-04-19 |
| Unknown | Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (F End Stage Renal Disease | Phase 3 | 2020-09-01 |
| Completed | Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and I End Stage Renal Disease | Phase 1 / Phase 2 | 2020-06-25 |
| Completed | A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation P End Stage Renal Disease | Phase 1 / Phase 2 | 2019-09-30 |
| Completed | Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Ad End Stage Renal Disease | Phase 1 / Phase 2 | 2017-10-01 |
| Terminated | Triferic IRIDA (Iron-Refractory Iron-Deficiency Anemia) Protocol Iron-Refractory Iron-Deficiency Anemia | Phase 2 | 2017-01-17 |
| Completed | Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis Peritoneal Dialysis (PD), Anemia, Chronic Kidney Disease | Phase 1 | 2017-01-01 |
| Completed | Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solu Iron-refractory, Iron-deficiency Anemia (IRIDA) | Phase 1 | 2016-04-01 |
| Completed | Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via He End Stage Renal Disease | Phase 1 | 2016-04-01 |
| Completed | Triferic Pediatric Pharmacokinetic Protocol End Stage Renal Disease | Phase 1 / Phase 2 | 2015-11-01 |
| Completed | Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunt End Stage Renal Disease | Phase 1 | 2015-10-01 |
| Completed | Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients Kidney Failure | Phase 1 / Phase 2 | 2013-07-01 |
| Completed | A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers Kidney Failure, Chronic Therapy; Hemodialysis | Phase 1 | 2013-06-01 |
| Completed | Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis End Stage Renal Disease, Chronic Kidney Disease | Phase 3 | 2011-11-01 |
| Completed | Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2) Renal Failure Chronic Requiring Hemodialysis | Phase 3 | 2011-04-01 |
| Completed | Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients Renal Failure Chronic Requiring Hemodialysis | Phase 3 | 2011-03-01 |
| Completed | Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients End Stage Renal Disease | Phase 2 | 2011-01-01 |
| Completed | Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) End-Stage Renal Disease (ESRD) | Phase 2 | 2007-08-01 |